Navoximod

DB15439InvestigationalSmall molecule

Navoximod is under investigation in clinical trial NCT02048709 (Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors).

Chemical structure of Navoximod
Mechanism
Curator reviewed
Formula / weight
C18H21FN2O2 · 316.376 g/mol (avg)
Code names
GDC-0919

Resolves to

Compound
UNII926SHL95NCCAS1402837-78-8ChEMBLCHEMBL3989951
Structure
InChIKeyYGACXVRLDHEXKY-WXRXAMBDSA-NSMILESO[C@H](C[C@@H]1N2C=NC=C2C2=CC=CC(F)=C12)[C@H]1CC[C@H](O)CC1
Targets
P14902IDO1

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
2Clinical trialsPhase, status and sponsor resolved per trial
Sign in
12+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Navoximod, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In